These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 18418219)

  • 21. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube.
    Noguera IR; Sun CC; Broaddus RR; Branham D; Levenback CF; Ramirez PT; Sood AK; Coleman RL; Gershenson DM
    Gynecol Oncol; 2012 Jun; 125(3):640-5. PubMed ID: 22387451
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer.
    Harshman LC; Li M; Srinivas S
    Am J Clin Oncol; 2008 Oct; 31(5):417-23. PubMed ID: 18838876
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.
    Motzer RJ; Hudes GR; Curti BD; McDermott DF; Escudier BJ; Negrier S; Duclos B; Moore L; O'Toole T; Boni JP; Dutcher JP
    J Clin Oncol; 2007 Sep; 25(25):3958-64. PubMed ID: 17761980
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
    Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
    Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma.
    Hainsworth JD; Spigel DR; Burris HA; Waterhouse D; Clark BL; Whorf R
    J Clin Oncol; 2010 May; 28(13):2131-6. PubMed ID: 20368560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II study of cisplatin and imatinib in advanced salivary adenoid cystic carcinoma.
    Ghosal N; Mais K; Shenjere P; Julyan P; Hastings D; Ward T; Ryder WD; Bruce I; Homer J; Slevin NJ
    Br J Oral Maxillofac Surg; 2011 Oct; 49(7):510-5. PubMed ID: 21071117
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma.
    Angevin E; Lopez-Martin JA; Lin CC; Gschwend JE; Harzstark A; Castellano D; Soria JC; Sen P; Chang J; Shi M; Kay A; Escudier B
    Clin Cancer Res; 2013 Mar; 19(5):1257-68. PubMed ID: 23339124
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy.
    Wyman K; Atkins MB; Prieto V; Eton O; McDermott DF; Hubbard F; Byrnes C; Sanders K; Sosman JA
    Cancer; 2006 May; 106(9):2005-11. PubMed ID: 16565971
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Final safety and efficacy analysis of a phase I/II trial with imatinib and vinorelbine for patients with metastatic breast cancer.
    Maass N; Schem C; Bauerschlag DO; Tiemann K; Schaefer FW; Hanson S; Muth M; Baier M; Weigel MT; Wenners AS; Alkatout I; Bauer M; Jonat W; Mundhenke C
    Oncology; 2014; 87(5):300-10. PubMed ID: 25171229
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multicenter phase II trial of combination therapy with meloxicam, a cox-2 inhibitor, and natural interferon-alpha for metastatic renal cell carcinoma.
    Shinohara N; Kumagai A; Kanagawa K; Maruyama S; Abe T; Sazawa A; Nonomura K
    Jpn J Clin Oncol; 2009 Nov; 39(11):720-6. PubMed ID: 19684042
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY).
    Bracarda S; Porta C; Boni C; Santoro A; Mucciarini C; Pazzola A; Cortesi E; Gasparro D; Labianca R; Di Costanzo F; Falcone A; Cinquini M; Caserta C; Paglino C; De Angelis V
    Eur Urol; 2013 Feb; 63(2):254-61. PubMed ID: 22964169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interferon-alpha-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma.
    Fosså SD; Mickisch GH; De Mulder PH; Horenblas S; van Oosterom AT; van Poppel H; Fey M; Croles JJ; de Prijck L; Van Glabbeke M
    Cancer; 2004 Aug; 101(3):533-40. PubMed ID: 15274066
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-α2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial.
    Bracarda S; Bellmunt J; Melichar B; Négrier S; Bajetta E; Ravaud A; Sneller V; Escudier B
    BJU Int; 2011 Jan; 107(2):214-9. PubMed ID: 20942831
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890).
    Dutcher JP; Fine JP; Krigel RL; Murphy BA; Schaefer PL; Ernstoff MS; Loehrer PJ
    Med Oncol; 2003; 20(3):271-81. PubMed ID: 14514977
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma.
    Tannir NM; Cohen L; Wang X; Thall P; Mathew PF; Jonasch E; Siefker-Radtke A; Pagliaro LC; Ng CS; Logothetis C
    Cancer; 2006 Nov; 107(9):2254-61. PubMed ID: 17029276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma.
    Dawson NA; Guo C; Zak R; Dorsey B; Smoot J; Wong J; Hussain A
    Clin Cancer Res; 2004 Dec; 10(23):7812-9. PubMed ID: 15585612
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II trial of gefitinib and pegylated IFNα in previously treated renal cell carcinoma.
    Shek D; Longmate J; Quinn DI; Margolin KA; Twardowski P; Gandara DR; Frankel P; Pan CX; Lara PN
    Int J Clin Oncol; 2011 Oct; 16(5):494-9. PubMed ID: 21431345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II trial of gefitinib in recurrent glioblastoma.
    Rich JN; Reardon DA; Peery T; Dowell JM; Quinn JA; Penne KL; Wikstrand CJ; Van Duyn LB; Dancey JE; McLendon RE; Kao JC; Stenzel TT; Ahmed Rasheed BK; Tourt-Uhlig SE; Herndon JE; Vredenburgh JJ; Sampson JH; Friedman AH; Bigner DD; Friedman HS
    J Clin Oncol; 2004 Jan; 22(1):133-42. PubMed ID: 14638850
    [TBL] [Abstract][Full Text] [Related]  

  • 39. STAT3 polymorphism can predict the response to interferon-α therapy in patients with metastatic renal cell carcinoma.
    Eto M; Kamba T; Miyake H; Fujisawa M; Kamai T; Uemura H; Tsukamoto T; Azuma H; Matsubara A; Nishimura K; Nakamura T; Ogawa O; Naito S;
    Eur Urol; 2013 Apr; 63(4):745-52. PubMed ID: 23063454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma.
    Drucker B; Bacik J; Ginsberg M; Marion S; Russo P; Mazumdar M; Motzer R
    Invest New Drugs; 2003 Aug; 21(3):341-5. PubMed ID: 14578682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.